Malignancy rates in patients with rheumatoid arthritis treated with tocilizumab

OBJECTIVE: To analyse malignancy rates in patients with rheumatoid arthritis (RA) treated with tocilizumab. METHODS: Patients who received tocilizumab or placebo+methotrexate/disease-modifying antirheumatic drugs in the double-blind phases of 5-phase three trials or who received at least 1 dose of t...

Descripción completa

Detalles Bibliográficos
Autores principales: Rubbert-Roth, Andrea, Sebba, Anthony, Brockwell, Laura, Kelman, Ariella, Porter-Brown, Benjamin, Pulley, Jennifer, Napalkov, Pavel, van Vollenhoven, Ronald F
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BMJ Publishing Group 2016
Materias:
Rheumatoid Arthritis
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4874056/
https://www.ncbi.nlm.nih.gov/pubmed/27252893
http://dx.doi.org/10.1136/rmdopen-2015-000213

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4874056/
https://www.ncbi.nlm.nih.gov/pubmed/27252893
http://dx.doi.org/10.1136/rmdopen-2015-000213

Ejemplares similares